Clinical trial · Observational
Long-Term Follow-Up Safety Study of Subjects Treated with SynKIR-110 in Cancer Studies
Long-Term Follow-Up Safety Study of Subjects Treated with SynKIR-110, Autologous T Cells Transduced with Mesothelin KIR-CAR, in Cancer Studies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study is being withdrawn and replaced by a new multicenter LTFU Basket Study, designed to monitor the long-term safety of all SynKIR CAR T cell products. This updated study will include all participants who have been treated with Verismo Therapeu
Summary
Brief summary (as posted)
The primary objective of this study is to evaluate the long-term safety of SynKIR- 110 administered to adult subjects with solid tumors expressing mesothelin.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Number of subjects with treatment related adverse events as assessed by CTCAE v5.0
- timeFrame
- 15 years from date subject received SynKIR-110
- description
- Monitor for signs of SynKIR-110 related delayed adverse events
Secondary outcomes (2)
- measure
- Number of subjects with persistence of SynKIR-110 modified cells
- timeFrame
- 15 years from date subject received SynKIR-110
- description
- Monitor qPCR of peripheral blood for persistence of SynKIR-110 modified T cells.
- measure
- Number of subjects with potential/suspected RCL
- timeFrame
- 15 years from date subject received SynKIR-110
- description
- Monitor qPCR of peripheral blood for VSV-G DNA
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Subjects who have received any amount of SynKIR-110 in a study sponsored by Verismo Therapeutics. 2. Adult 18 years of age or older Exclusion Criteria: 1. Unable or unwilling to provide written informed consent 2. Unable or unwilling to comply with the study requirements
References
Publications (0)
Data not yet available